Health Plans Embrace Biosimilars to Reduce Costs and Improve Patient Access | AMCP Nexus 2024 How health plans are implementing strategies to leverage biosimilars to lower costs for both payers and ...

How health plans are implementing strategies to leverage biosimilars to lower costs for both payers and patients.

Cynthiya Ruban, Ph.D., M.S., Director of Digital Solutions at Cencora says to keep the following in mind as AI use accelerates.

The role of AI is ever-evolving, especially for healthcare decision makers, according to Cynthiya Ruban, Ph.D., M.S., Director of Digital Solutions at Cencora. AI leads to an increase in ...

It's not the multimillion dollar prices, says Kevin Niehoff, Pharm.D., of IPD Analytics. The pool of sickle cell disease patients who are prime candidates for sickle cell disease gene therapy was ...

Two years after treatment, both girls show normal motor function and no signs of spinal muscular atrophy symptoms.

Drs Martin Rosenzweig and Samuel Nordberg share perspectives for integrated policymaking in behavioral health, as well as payer and provider collaboration for TRD.

Steven Levine, MD: Carrie, can you talk about what’s involved in procuring intranasal esketamine [Spravato], the various routes, whether that’s buy-and-bill or specialty pharmacy, and any of the ...

Carrie Jardine leads a discussion on varying prior authorization policies for alternative therapies for TRD along with implications to patients.

Those complexities extend to billing and coding. Sometimes navigating these complexities is a reason for patients who are ...

Dr Patricia Ares-Romero and Dr Martin Rosenzweig discuss treatment strategies for TRD, including alternative therapies and explain current barriers within the healthcare system that inhibit access.

Imuldose will be marketed in the United States by Accord BioPharma and is expected to launch in the first half of 2025.